

Strong growth: Leukocare moves into new headquarters at the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried/Planegg

Martinsried/Munich, 05.07.2021

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced today that, due to strong growth and related demand for extra space, it has moved its headquarters from existing premises at the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried/Planegg near Munich to a new and state-of-the-art building on the same campus. The number of employees has more than tripled in the last three years and so has the need for research laboratories and office space. Modern offices and laboratories with an area of approx. 2,000 m² (21.000 sqf) provide Leukocare sufficient flexibility for future growth. The focus of the new work environment lies on an efficient lab design and activity-based flexible offices enabling fruitful and interdisciplinary collaboration between all departments.

Michael Scholl, CEO of Leukocare, said, "The IZB in Martinsried is the ideal location for us. The combination of state-of-the-art offices and adjoining research laboratories is unique and precisely tailored to our needs. We are delighted that we are able to stay here and expand our premises significantly. Special thanks go to the IZB team led by Dr. Zobel. By flexibly providing ever increasing building space, the IZB has actively supported our steady growth in recent years. I am particularly pleased that the distribution of the Leukocare team over several IZB buildings has come to an end, and that we will be back to working collaboratively in one space in an agile manner and with short lines of communication."

Dr. Peter Hanns Zobel, Managing Director IZB, commented, "We are very pleased that we can offer prospects to a successful biotech company like Leukocare, currently experiencing dynamic growth. This shows that the companies based here in Martinsried appreciate the existing infrastructure and networking. I am delighted that we could keep such an innovative company like Leukocare here on our campus at the IZB."

Leukocare's headquarters have been located in the international biotechnology hub in Martinsried since 2010. The company benefits from both the infrastructure of modern office and laboratory space and the scientific network surrounding the biotechnology cluster. In addition to its headquarters in Martinsried, Leukocare expanded its US activities in January 2021 with the opening of development laboratories and offices in Milford, Massachusetts.

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs.

Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Contact:

Leukocare AG

Rebekka Ströver

Specialist Communications & Marketing

rebekka.stroeever@leukocare.com

+ 49 (0) 89 7801 665 14